annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 46B ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with
advanced non-small cell lung cancer (NSCLC): Results of a phase II,
randomized, double-blind, placebo-controlled trial. (Abstract #7631)
M. Schuster, J. R. Rigas, S. V. Orlov, B. Milovanovic, K. Prabhash, J. T. Smith, and
the ALD518 Study Group
Brd. 46C HIV-associated lung cancer in the era of highly active antiretroviral therapy
(HAART): Correlation between CD4 count and outcome. (Abstract #7632)
S. Pakkala, Z. Chen, D. Rimland, T. K. Owonikoko, C. Gunthel, J. C. Brandes,
N. F. Saba, W. J. Curran Jr., F. R. Khuri, S. S. Ramalingam
Brd. 46D Survival impact of newly approved therapeutic agents in patients with
advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database
analysis. (Abstract #7633)
T. K. Owonikoko, S. S. Ramalingam, M. Behera, J. C. Brandes, N. F. Saba,
C. Bhimani, S. Harichand-Herdt, D. M. Shin, F. R. Khuri, C. Ragin
Brd. 46E First-line systemic therapy in metastatic non-small cell lung cancer
(mNSCLC) patients treated at National Comprehensive Cancer Network
(NCCN) institutions: An analysis from the NCCN Oncology Outcomes
Database Project. (Abstract #7634)
J. L. Vandergrift, R. Mamet, C. Zornosa, M. E. Reid, M. S. Rabin, D. S. Ettinger,
G. P. Kalemkerian, G. A. Otterson, J. C. Niland, K. Pisters, NCCN Oncology
Outcomes Database Non-Small Cell Lung Cancer Disease Specific Executive
Committee
Brd. 46F Brain metastases (mets) in lung cancer patients (pts): Analysis of the Detroit
Surveillance, Epidemiology and End Results (SEER) data. (Abstract #7635)
S. M. Gadgeel, R. Goveas, F. Vigneau, W. Quarshie, M. Islam, A. Schwartz,
A. J. Wozniak, M. Cote
Brd. 46G Prognostic impact of malignant pleural effusion in patients with stage M1b
non-small cell lung cancer. (Abstract #7636)
D. Morgensztern, S. N. Waqar, D. I. Kuperman, B. W. Goodgame, K. Trinkaus,
R. Govindan
Brd. 46H Tumor response and progression-free survival (PFS) as potential surrogate
endpoints for overall survival (OS) in extensive-stage small cell lung cancer
(ES-SCLC): Findings based on North Central Cancer Treatment Group
(NCCTG) trials. (Abstract #7637)
N. R. Foster, Y. Qi, Q. Shi, J. E. Krook, J. W. Kugler, J. R. Jett, J. R. Molina,
S. E. Schild, A. A. Adjei, S. J. Mandrekar
Brd. 47A Ethnic difference in toxicity in non-small cell lung cancer patients treated
with chemotherapy: A systematic review on phase II and III clinical trials.
(Abstract #7638)
Y. Hasegawa, T. Kawaguchi, A. Kubo, M. Ando, J. Shiraishi, S. Isa, T. Tsuji,
K. Tsujino, K. Nakagawa, M. Takada
Brd. 47B Improving the accuracy of FNA lung biopsies in a community hospital.
(Abstract #7639)
A. Higgins, A. R. Calvo, R. Pelstring
222